Gousto Founder Decries Weight-Loss Jab Reliance as 'Depressing State of Affairs'
Gousto founder Timo Boldt has launched a scathing critique of the growing dependence on weight-loss medications, labeling the trend a "depressing state of affairs" that fails to confront the underlying issues in Britain's food system. Speaking exclusively to Capital Post, Boldt emphasized that while GLP-1 drugs like Ozempic and Mounjaro might offer temporary solutions, they cannot replace the necessity for fundamental dietary habit changes.
The Addictive Nature of Ultra-Processed Foods
Boldt recently collaborated with London School of Economics food scientists to create "The Big Secret" burger, a hypothetical fast-food meal designed to be the world's most addictive. This provocative stunt aimed to highlight how food manufacturers engineer products to trigger dopamine responses—known as the "bliss point"—by combining fat, salt, and sugar in precise ratios.
"This food is highly addictive," Boldt explains. "It's all geared toward preventing you and me from stopping eating. People are trying to engineer this 'bliss point,' where they combine fat, salt, and sugar to find the point where you can't stop eating and can't shake off the cravings."
The result is meals like the hypothetical burger, which would deliver over 165% of daily salt intake, triple the sugar limit, and extremely high saturated fat levels in just a few bites.
Failed Government Interventions and Persistent Problems
Despite numerous government initiatives—from George Osborne's sugar tax to Boris Johnson's proposed snack taxes and Wes Streeting's current efforts to tax sugary milkshakes—Britain's food system remains among the least healthy in the developed world. Only the United States surpasses the UK in unhealthy supermarket offerings.
The consequences are stark: two-thirds of British adults are overweight or obese, costing taxpayers an estimated £6.5 billion annually—equivalent to half the entire Ministry of Justice budget.
The Pharmaceutical 'Solution' and Its Limitations
Weight-loss jabs have been hailed as miracle solutions to the global obesity crisis, driving stock market rallies for pharmaceutical companies. However, Boldt argues that medicating away decades of poor dietary habits without addressing root causes is fundamentally flawed.
"GLP-1 drugs, in certain situations, are probably the right thing to do," Boldt acknowledges. "But fundamentally, even if you take them, you still have to change your habits. And changing habits is incredibly difficult."
He notes that despite their potential, these drugs have seen slow NHS rollout and limited national impact due to their needle-based delivery methods and accessibility issues.
The Need for Systemic Food System Reform
Boldt founded Gousto in 2012 with the mission to reduce food waste and promote healthier eating through meal kits. The company's Warrington warehouse prepares approximately 140 million meal kits annually, with only 12% classified as highly processed compared to 60% in the general population's diet.
"We are seeing an uptick in demand for healthy food," Boldt reports. "And theoretically we are positioned exceptionally well to benefit from this because the healthiest way to eat is cooking from scratch. But we haven't really seen it in the numbers, I would argue, beyond that general increase in healthy eating."
Innovative Approaches and Future Directions
Some companies are exploring novel combinations of traditional health incentives with pharmaceutical approaches. Boots recently announced plans to offer 25% discounts on weight-loss jabs to patients who complete 5km weekend jogs through a partnership with health insurer Vitality.
Boldt sees similar potential for Gousto: "We have to work with insurance companies to lower premiums for people who eat healthily. Frankly, if you're a Gousto customer, you should get cheaper health insurance."
Resilience Against Technological Disruption
Despite predictions that artificial intelligence might render meal delivery services obsolete by enabling direct communication between consumer agents and supermarket systems, Boldt remains confident in Gousto's future. The company's "moat" lies in its customer data, supply chain expertise, and pre-proportioned ingredients—advantages that supermarket recipe services have failed to replicate.
"What people see on their menu is AI-driven," Boldt explains. "So you should never see on your feed what I'm seeing—we should have totally different experiences. But the moat is actually the data we have about the customer and the supply chain."
The Persistent Appeal of Unhealthy Choices
Even as a health advocate, Boldt acknowledges that Gousto customers still gravitate toward comforting, indulgent dishes alongside healthier options. The menu includes cheesy pasta bakes and fish and chips alongside promoted nutritious meals.
"When you ask people, 'What do you want to eat?' People tend to say salad," Boldt observes. "But when you look at what people actually eat, they still like burgers and fries."
This reality underscores the monumental challenge facing both public health advocates and policymakers: changing deeply ingrained eating behaviors in a food environment engineered for addiction.
